Predicted protein targets (top 7)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | GAA | P10253 | 1/20 | 0.57 |
| ▸ | NFKB1 | P19838 | 4/20 | 0.45 |
| ▸ | NFKB2 | Q00653 | 4/20 | 0.45 |
| ▸ | RELA | Q04206 | 4/20 | 0.45 |
| ▸ | EPHX2 | P34913 | 1/20 | 0.42 |
| ▸ | NAAA | Q02083 | 6/20 | 0.39 |
| ▸ | BTK | Q06187 | 1/20 | 0.38 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL9811323 | 1.00 | GAA (0.57) | GAANFKB1NFKB2RELAEPHX2 | |
| SCHEMBL9811313 | 1.00 | GAA (0.57) | GAANFKB1NFKB2RELAEPHX2 | |
| SCHEMBL2327582 | 0.83 | GAA (0.60) | GAANFKB1NFKB2RELAEPHX2 | |
| SCHEMBL15199916 | 0.83 | GAA (0.60) | GAANFKB1NFKB2RELAEPHX2 | |
| SCHEMBL8197462 | 0.83 | GAA (0.60) | GAANFKB1NFKB2RELAEPHX2 | |
| SCHEMBL9811256 | 0.83 | GAA (0.43) | GAANFKB1NFKB2RELAEPHX2 | |
| SCHEMBL9811260 | 0.83 | GAA (0.43) | GAANFKB1NFKB2RELAEPHX2 | |
| SCHEMBL9811317 | 0.82 | NAAA (0.42) | GAANFKB1NFKB2RELAEPHX2 | |
| SCHEMBL9811309 | 0.82 | NAAA (0.42) | GAANFKB1NFKB2RELAEPHX2 | |
| SCHEMBL23513495 | 0.75 | GAA (0.59) | GAANFKB1NFKB2RELAEPHX2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 15 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-11746111-B2 | Siderophore conjugated pyrazolidinones, and analogues thereof | YALE UNIVERSITY (US) | 2023-09-05 | — | — | US | disclosed |
| EP-0202795-B1 | 4-SUBSTITUTED DIAZOLIDINONES | ELI LILLY AND COMPANY (US) | 1991-06-12 | — | — | EP | disclosed |
| US-5011938-A | Antimicrobials | ELI LILLY AND COMPANY (US) | 1991-04-30 | — | — | US | disclosed |
| US-4940718-A | BACTERICIDES | ELI LILLY AND COMPANY (US) | 1990-07-10 | — | — | US | disclosed |
| US-4826993-A | Substituted diazolidinones | ELI LILLY AND COMPANY (US) | 1989-05-02 | — | — | US | disclosed |
| EP-0310214-A2 | 7-Substituted bicyclic pyrazolidinones | ELI LILLY AND COMPANY (US) | 1989-04-05 | — | — | EP | disclosed |
| US-4795815-A | BACTERICIDES, MICROBIOCIDES | ELI LILLY AND COMPANY (US) | 1989-01-03 | — | — | US | disclosed |
| US-4767871-A | Pyrazolidinium ylides | ELI LILLY AND COMPANY (US) | 1988-08-30 | — | — | US | disclosed |
| US-4734504-A | 1-alkylated diazolidinones | ELI LILLY AND COMPANY (US) | 1988-03-29 | — | — | US | disclosed |
| US-4734505-A | 1-(alkylated)-2-(acylated)diazolidinones | ELI LILLY AND COMPANY (US) | 1988-03-29 | — | — | US | disclosed |
| US-4716232-A | 1-(vinyl phosphonate adduct) pyrazolidinones | ELI LILLY AND COMPANY (US) | 1987-12-29 | — | — | US | disclosed |
| EP-0202794-A1 | 7-Substituted-2,3-(Dihydro) bicyclic pyrazolidinones | ELI LILLY AND COMPANY (US) | 1986-11-26 | — | — | EP | disclosed |
| EP-0202795-A1 | 4-Substituted diazolidinones | ELI LILLY AND COMPANY (US) | 1986-11-26 | — | — | EP | disclosed |
| EP-0202047-A1 | Pyrazolidinium ylides | ELI LILLY AND COMPANY (US) | 1986-11-20 | — | — | EP | disclosed |
| EP-0202046-A1 | 7-Substituted bicyclic pyrazolidinones | ELI LILLY AND COMPANY (US) | 1986-11-20 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-11746111-B2 | Siderophore conjugated pyrazolidinones, and analogues thereof | SLC40A1, HAMP, SLC39A11 | GAA 2359/4885NFKB1 3070/4885NFKB2 3676/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.